Reversal of ketosis in type 1 diabetes is not adversely affected by SGLT2 inhibitor therapy

Stephan Siebel, Alfonso Galderisi, Neha S. Patel, Lori R. Carria, William V. Tamborlane, Jennifer L. Sherr

Research output: Contribution to journalArticle

Abstract

Objective: We have shown that "euglycemic DKA" in patients with type 1 diabetes receiving a sodium-glucose cotransporter 2-inhibitor (SGLT2i) is due to normal increases in rates of ketogenesis but blunted increases in plasma glucose levels. In this analysis, we assessed whether rescue treatment of early ketoacidosis with insulin is altered by SGLT2i use. Research Design and Methods: Participants received 0.2 U/kg of aspart insulin after two 6-h interruptions of basal insulin that increased beta-hydroxybutyrate (BHB) by 1.2 ± 0.7 mmol/L before and by 1.5 ± 0.2 mmol/L during canagliflozin treatment. BHB and free fatty acid (FFA) were monitored every 30 min for 120 min after receiving a 0.2 U/kg subcutaneous injection of aspart insulin. Results: Ten adults (23 ± 5 years) were studied. During the 120 min after rescue therapy with insulin, the reductions in BHB and FFA were nearly identical between the pre- and during canagliflozin treatment studies, respectively (-1.27 ± 0.76 and -1.13 ± 0.69, P = 0.671 for BHB and -0.50 ± 0.35 vs. -0.41 ± 0.41, P = 0.603 for FFA). Conclusion: These data indicate that turning ketogenesis off, as well as on, does not appear to be affected by SGLT2i use.

Original languageEnglish (US)
Pages (from-to)101-104
Number of pages4
JournalDiabetes Technology and Therapeutics
Volume21
Issue number3
DOIs
StatePublished - Mar 2019

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Reversal of ketosis in type 1 diabetes is not adversely affected by SGLT2 inhibitor therapy'. Together they form a unique fingerprint.

  • Cite this